Clinical Trial Update: An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis [Phase 3]

View source ↗

Summary

A Phase 3 open-label randomized trial evaluating a short course of paromomycin for visceral leishmaniasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Visceral Leishmaniasis

Drugs mentioned

• Paromomycin (paromomycin)

Snippet

Sponsor: Banaras Hindu University | Conditions: Visceral Leishmaniasis | Phase 3 | Status: COMPLETED